BioSpace News Archive

Soligenix, Inc. announced today that it has signed a worldwide exclusive license to supply its ricin antigen to SERB Pharmaceuticals (SERB), for development of a novel therapeutic treatment against ricin toxin poisoning.

As the nation’s premier authority in cardiometabolic medicine, CMHC’s events are curated by the field’s leading experts to deliver the latest evidence-based interventions to improve health outcomes and quality of life for the growing number of patients at increased cardiometabolic risk.

Centessa Pharmaceuticals plc today announced the appointment of Harris L. Rotman, PhD, as Senior Vice President, Regulatory Affairs.

Ashvattha Therapeutics (“Ashvattha”), a clinical stage company developing novel hydroxyl dendrimer therapeutics, today announced the publication of the results from a Phase 2a clinical study demonstrating a significant reduction in inflammatory and neuroinflammatory markers and improved clinical outcomes with OP-101, a hydroxyl dendrimer therapeutic (HDT), delivered intravenously in patients with severe COVID-19.

IceCure Medical Ltd today announced the submission of a regulatory filing with the Canadian governmental agency, Health Canada.

Nobelpharma America, LLC will debut HYFTOR ™ (sirolimus topical gel) 0.2%, the first-ever U.S. FDA-approved topical treatment for facial angiofibroma associated with tuberous sclerosis complex (TSC) for patients 6 years and older at the 2022 World TSC Conference at the Hilton Anatole Hotel in Dallas, Texas, from July 28-31, 2022.

Company reiterates support of proposals for the authorization to increase number of shares available for issuance by the Company and authorization for the Board to effect a reverse stock split at their discretion.

Aviceda Therapeutics, Inc. announced today the appointment of Tarek S. Hassan, MD, FASRS as Chief Development Officer and Senior Vice-President.

Enzychem Lifesciences (KOSDAQ: 183490), a late-stage biopharmaceutical company, announced today the acceptance of a poster presentation at the Radiation Research Society (RRS) 2022 Annual Meeting, which will be held in Waikoloa, Hawaii on October 16-19, 2022.

Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will report second quarter ended June 30, 2022 financial results after the close on Monday, August 8, 2022.